Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.
Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.
Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases.
Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.
NexCure offers clinically intense therapies in outpatient, community settings, and other cutting-edge treatments.
Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Zura Bio is a clinical-stage, multi-asset biotechnology company.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases.
RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Therapeutics, Medical, Health Care, Life Science. The firm invests across 13 different industry categories.
Among tracked funding rounds, Candid Therapeutics received $505.0M in a Undisclosed round. RA Capital Management's total known invested capital is $44.2B.
RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.
Recent RA Capital Management portfolio additions include Aiolos Bio, Alpha-9 Oncology, Harpoon Therapeutics, Electra Therapeutics, Rani Therapeutics. These companies were founded in 2020 or later.